Immuron Limited
As of Oct 22, 2026, Immuron is in Stage 3, the topping phase, now in week 2 (since Oct 12, 2026). It closed at $0.95, 56.9% below its 52-week high and below its 200-day average, which is rising.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IMRN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IMRN among Biotechnology387th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …387 | IMRN | Stage 3 · wk 2 | 19 | −18.9% |
Immuron: quick answers
What stage is Immuron in?
As of Oct 22, 2026, Immuron (IMRN) is in Stage 3, the topping phase. It entered Stage 3 on Oct 12, 2026 and is in week 2. What the four stages mean
Is Immuron in an uptrend?
Its uptrend has stalled. Immuron is in Stage 3, the topping phase that follows an advance. It trades 6.6% below its 200-day average, which is rising.
How far is Immuron from its 52-week high?
Immuron closed at $0.95 on Oct 22, 2026, 56.9% below its 52-week high of $2.20. Its 52-week low is $0.70.
How has Immuron performed over the past year?
As of Oct 22, 2026, Immuron is down 58.1% over the past year and up 19.4% so far in 2026.
Which sector and industry is Immuron in?
Immuron is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IMM-529, which is in Phase II clinical trial for the treatment of Clostridioides difficile infection. In addition, the company offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.